22:23 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Cancer antigens from RNA edits

A team from Immatics Biotechnologies GmbH and University of Texas MD Anderson Cancer Center has shown that cancer antigens generated via post-transcriptional RNA editing could further broaden the target space for immunotherapies. The study ,...
22:30 , Jun 8, 2017 |  BC Innovations  |  Finance

The bio-tech bridge

Last year’s flurry of interest from tech titans has brought a wealth of new funding to translational science that is gaining them status as new and important players in the biotech ecosystem. With a heavy...
08:00 , Feb 22, 2016 |  BioCentury  |  Emerging Company Profile

Oncolytic immunotherapy

Turnstone Biologics Inc. is combining an oncolytic virus with cancer vaccines, which it anticipates will result in products with efficacy advantages over each individual modality. Turnstone's origins trace to the Ottawa Hospital Research Institute lab...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Nextera, J&J deal

Nextera and Johnson & Johnson’s Janssen Biotech Inc. unit partnered to develop Nextera’s platform for rheumatoid arthritis. Nextera will undertake studies to verify the applicability of the technology for RA. Janssen will fund the research...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

MorphoSys, immatics deal

The companies partnered to develop antibodies against undisclosed cancer targets recognized by T cells. MorphoSys will gain access to an undisclosed number of immatics’ tumor-associated peptides (TUMAPs), which MorphoSys will use to develop antibodies to...
02:05 , Aug 26, 2015 |  BC Extra  |  Company News

MorphoSys, immatics enter immuno-oncology deal

MorphoSys AG (Xetra:MOR; Pink:MPSYF) partnered with immatics biotechnologies GmbH (Tuebingen, Germany) to develop antibodies against undisclosed cancer targets recognized by T cells. MorphoSys will gain access to an undisclosed number of immatics' tumor-associated peptides (TUMAPs),...
08:00 , Jan 29, 2015 |  BC Innovations  |  Targets & Mechanisms

Personalized tumor vaccines

Although the jury is in on the role of PD-1 inhibitors in enabling T cell activation in cancer, it is still unclear which tumor epitopes are targeted by the T cells or whether those epitopes...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

immatics, Roche deal

immatics partnered with Roche to develop and commercialize cancer vaccines and immunotherapies containing tumor-associated peptides (TUMAPs). Roche will be responsible for the clinical development of a "number" of TUMAP-based cancer vaccines, including immatics' IMA942 ,...
01:29 , Nov 14, 2013 |  BC Extra  |  Company News

immatics, Roche in cancer vaccine deal

immatics biotechnologies GmbH (Tuebingen, Germany) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize cancer vaccines and immunotherapies containing tumor-associated peptides (TUMAPs), including immatics' IMA942 . Roche will be responsible for the clinical development of...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

BioNTech, immatics cancer news

The Glioma Actively Personalized Vaccine Consortium (GAPVAC) received €6 million ($7.8 million) in funding from the EU's Framework Programme 7 (FP7) to develop a new class of therapeutic cancer vaccines for brain cancer patients. The...